The Desmoid Tumor Research Foundation

May 2018

Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response

Author Information

Libertini M(1), Mitra I(1)(2), van der Graaf WTA(1)(3), Miah AB(1)(3), Judson I(1)(3), Jones RL(1)(3), Thomas K(2), Moskovic E(1)(3), Szucs Z(1), Benson C(1), Messiou C(1)(2)(3).

(1)Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, UK. (2)Department of Radiology, The Royal Marsden NHS Foundation Trust, 203 Fulham Road, London, SW3 6JJ UK. (3)Institute of Cancer Research, Sutton, UK.

Publication

Clin Sarcoma Res

Summary

One of the commonly used systemic agents for the treatment of aggressive fibromatosis(AF) is the anti-oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, consisting mainly of small case series and reports. A retrospective database was used to identify consecutive patients diagnosed with AF and treated with tamoxifen plus/minus non-steroidal anti-inflammatory drugs at our tertiary referral centre between 2007 and 2014. No relationship was identified between symptomatic benefit and response by RECIST 1.1 on MRI. Prospective studies in AF should incorporate endpoints focusing on patient symptoms.

View Abstract